FDA Approves Periostat Generics, But Launch Could Hinge On Patent Case
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves three ANDAs for Periostat tablets and one for the capsule formulation. In a patent infringement lawsuit, Periostat marketer CollaGenex is requesting that a federal court preliminarily enjoin launches by Ivax and CorePharma.
You may also be interested in...
CollaGenex' Oracea Rosacea Therapy Could Launch Third Quarter 2006
Firm announces NDA submission for the rosacea therapy. As the first oral systemic rosacea treatment, Oracea could expand the market, CollaGenex says.
CollaGenex' Oracea Rosacea Therapy Could Launch Third Quarter 2006
Firm announces NDA submission for the rosacea therapy. As the first oral systemic rosacea treatment, Oracea could expand the market, CollaGenex says.
D.C. Court Upholds FDA Classification Of CollaGenex' Periostat
D.C. federal judge agrees with FDA's argument that Periostat should be classified as an antibiotic since it contains the drug doxycycline, which was previously classified as an antibiotic. CollaGenex is seeking a separate injunction to prevent Ivax and CorePharma from marketing generic versions of the periodontal agent.